DRUG-INDUCED HAIR LOSS AND HAIR-GROWTH - INCIDENCE, MANAGEMENT AND AVOIDANCE

被引:84
作者
TOSTI, A
MISCIALI, C
PIRACCINI, BM
PELUSO, AM
BARDAZZI, F
机构
[1] Department of Dermatology, University of Bologna, Bologna, 40138
关键词
D O I
10.2165/00002018-199410040-00005
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
A large number of drugs may interfere with the hair cycle and produce hair loss. Drugs may affect anagen follicles through 2 main different modalities: (i) by inducing an abrupt cessation of mitotic activity in rapidly dividing hair matrix cells (anagen effluvium) or (ii) by precipitating the follicles into premature rest (telogen effluvium). In anagen effluvium, hair loss usually occurs within days to weeks of drug administration, whereas in telogen effluvium, hair loss becomes evident 2 to 4 months after starting treatment. Anagen effluvium is a prominent adverse effect of antineoplastic agents, which cause acute damage of rapidly dividing hair matrix cells. Telogen effluvium may be a consequence of a large number of drugs including anticoagulants, retinol (vitamin A) and its derivatives, interferons and antihyperlipidaemic drugs. Drug-induced hair loss is usually reversible after interruption of treatment. The prevalence and severity of alopecia depend on the drug as well as on individual predisposition. Some drugs produce hair loss in most patients receiving appropriate dosages while other drugs are only occasionally responsible for hair abnormalities. Both hirsutism and hypertrichosis may be associated with drug administration. Drugs most commonly responsible for the development of hirsutism include testosterone, danazol, corticotrophin (ACTH), metyrapone, anabolic steroids and glucocorticoids. Hypertrichosis is a common adverse effect of cyclosporin, minoxidil and diazoxide.
引用
收藏
页码:310 / 317
页数:8
相关论文
共 42 条
[1]  
Baldelli A., Rebora A., Telogen effluvium and minoxidil, Journal of the American Academy of Dermatology, 21, pp. 572-573, (1989)
[2]  
Bencini P.L., Montagnino G., Sala F., Et al., Cutaneous lesions in 67 cyclosporin-treated renal transplant recipients, Dermatologica, 172, pp. 24-30, (1986)
[3]  
Buhl A.E., Waldon S.J., Conrad M.J., Et al., Potassium channel conductance: a mechanism affecting hair growth both in vitro and in vivo, Journal of Investigative Dermatology, 98, pp. 315-319, (1992)
[4]  
Burton J.L., Schutt W.H., Caldwell I.W., Hypertrichosis due to diazoxide, British Journal of Dermatology, 93, pp. 707-711, (1975)
[5]  
Caputo R., Monti M., Motta S., Et al., The treatment of visible signs of senescence: the Italian experience, British Journal of Dermatology, 112, 35, pp. 97-103, (1990)
[6]  
Cohen D.J., Loertscher R., Rubin M.F., Et al., Cyclosporine: a new immunosuppressive agent for organ transplantation, Annals of Internal Medicine, 10, pp. 667-682, (1984)
[7]  
Cornbleet T., Hoit L., Alopecia from coumarin, Archives of Dermatology, 75, pp. 440-441, (1957)
[8]  
Dawber R., Mortimer P., Hair loss during lithium treatment, British Journal of Dermatology, 107, pp. 124-125, (1982)
[9]  
Dean J.C., Salmon S.E., Griffith K.S., Prevention of doxorubicin-in-duced hair loss with scalp hypothermia, New England Journal of Medicine, 301, pp. 1427-1429, (1979)
[10]  
Delaunay M., Effets cutanés indésirables de la chimiothérapie antitumorale, Annales de Dermatologie et de Vénéréologie, 116, pp. 347-361, (1989)